1st Quarter - Report

NVG, LLC for ACCENDRA HEALTH INC.

Firm
Client
Income
$80,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Issues related to diabetes management and durable medical equipment reimbursement channels. Issues related to Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Competitive Bidding Updates and DMEPOS accreditation requirements in DMEPOS Calendar Year 2026 Final Rule. H.R.2902/S.1406 - Supplemental Oxygen Access Reform (SOAR) Act of 2025. S.4037 - Diabetes Interventions Addressing Barriers to Enrollment, Technology, and Education Services (DIABETES) Act.

LobbyistCovered position, as disclosed
LISA GERMAN FOSTER —
BRADY KING —
JANE LOEWENSON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2902 (119th), S. 1406 (119th), S. 4037 (119th)

Budget/Appropriations BUD

Report language for FY2027 Appropriations related to changes in the Competitive Bidding Program.

LobbyistCovered position, as disclosed
LISA GERMAN FOSTER —
BRADY KING —
JANE LOEWENSON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.